List of Excipients in Branded Drug FOCINVEZ

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Amneal Pharmaceuticals LLC	FOCINVEZ	fosaprepitant dimeglumine	70121-2631	BETADEX SULFOBUTYL ETHER SODIUM
Amneal Pharmaceuticals LLC	FOCINVEZ	fosaprepitant dimeglumine	70121-2631	EDETATE DISODIUM
Amneal Pharmaceuticals LLC	FOCINVEZ	fosaprepitant dimeglumine	70121-2631	SODIUM HYDROXIDE

Focinvez Excipient Strategy and Commercial Opportunities

Last updated: August 24, 2026

Focinvez is a 150 mg intravenous fosaprepitant product used to prevent acute and delayed chemotherapy-induced nausea and vomiting. Its commercial position depends less on new pharmacology than on formulation reliability, infusion compatibility, supply-chain control, and differentiation from Emend and other fosaprepitant products. The core excipient platform uses polysorbate 80, disodium edetate, lactose, sodium hydroxide, and hydrochloric acid in a lyophilized powder for reconstitution.[1]

The strongest commercial opportunities are in hospital formulary substitution, supply security, lower-cost generic procurement, ready-to-use presentations, pediatric and oncology-clinic formats, and formulation improvements that reduce preparation time or surfactant-related concerns. Focinvez is an EU-authorized product. Its regulatory and commercial analysis should be separated from U.S. fosaprepitant products because Focinvez itself is not an FDA-approved brand or an Orange Book-listed product.

What is Focinvez and how is it administered?

Focinvez contains fosaprepitant dimeglumine, an intravenous prodrug of aprepitant. Fosaprepitant is converted to aprepitant after administration and blocks the neurokinin-1 receptor. The product is used with other antiemetic agents in adults and selected pediatric patients receiving moderately or highly emetogenic chemotherapy.[1]

Attribute	Focinvez position
Active ingredient	Fosaprepitant dimeglumine
Strength	150 mg
Dosage form	Powder for solution for infusion
Route	Intravenous infusion
Therapeutic area	Chemotherapy-induced nausea and vomiting
Reference product	Emend IV
Regulatory region	European Union
Primary buyers	Hospitals, oncology centers, pharmacy purchasing groups
Formulation sensitivity	Reconstitution, dilution, infusion compatibility, surfactant stability
Primary commercial comparator	Emend and other fosaprepitant products

The product is administered as an intravenous infusion after reconstitution and dilution. It is not interchangeable with oral aprepitant solely on the basis of active-moiety content. Hospitals select between intravenous fosaprepitant, oral aprepitant, and alternative antiemetic regimens based on chemotherapy protocol, vomiting risk, swallowing ability, adherence, pharmacy workflow, and acquisition cost.

What excipients are used in Focinvez?

Focinvez uses a conventional sterile lyophilized formulation designed to stabilize fosaprepitant during storage and permit reconstitution before infusion. The publicly available product information identifies the following excipients:

Excipient	Formulation role	Commercial and technical relevance
Polysorbate 80	Solubilization and stabilization	Can create supply, oxidation, peroxide, extractables, and compatibility considerations
Disodium edetate	Chelation	Controls trace-metal effects and may support chemical stability
Lactose	Bulking and cake formation in the lyophilized product	Creates carbohydrate-related labeling and compatibility considerations
Sodium hydroxide	pH adjustment	Supports target formulation pH
Hydrochloric acid	pH adjustment	Used with sodium hydroxide to establish formulation conditions

The product information identifies lactose as an excipient. This matters for procurement and labeling because some hospital systems screen injectable products for lactose, even when the quantity is low and the clinical relevance differs from oral lactose-containing medicines.[1]

The formulation is not a simple aqueous solution. The lyophilized presentation reduces the time that fosaprepitant remains in a water-containing environment during storage. That approach can improve shelf-life and reduce the risk of hydrolysis or other solution-phase degradation. The tradeoff is added pharmacy preparation, reconstitution variability, and dependence on validated diluent and infusion procedures.

Why is polysorbate 80 strategically important in Focinvez?

Polysorbate 80 is the most commercially significant excipient in the Focinvez platform. It is widely used as a nonionic surfactant, but its quality profile can vary according to raw-material source, manufacturing process, peroxide content, fatty-acid composition, and degradation behavior.

For Focinvez, the key risks are:

1. Oxidative degradation and peroxide formation.
2. Lot-to-lot variability in surfactant composition.
3. Potential interaction with container-closure materials.
4. Extractables and leachables from manufacturing or administration components.
5. Dependence on a limited number of qualified pharmaceutical-grade suppliers.
6. Difficulty replacing the surfactant without repeating substantial formulation and stability work.

Polysorbate 80 also creates a potential differentiation path. A competing product could pursue a surfactant-reduced or surfactant-free formulation if it can maintain solubility, chemical stability, sterility assurance, reconstitution performance, and clinical comparability.

That opportunity is technically demanding. Fosaprepitant is formulated for parenteral administration, and removal of polysorbate 80 may increase precipitation or adsorption risk. Any replacement strategy would need to address:

• Solubility at the target concentration.
• Reconstitution time.
• Visible and subvisible particulate levels.
• Infusion-line compatibility.
• Diluent compatibility.
• Container-closure adsorption.
• Freeze-drying cycle performance.
• Stability after reconstitution and dilution.
• Local tolerability and infusion-related reactions.

A practical near-term strategy is not immediate excipient replacement. It is tighter control of polysorbate specifications, including peroxide limits, fatty-acid profile, water content, and degradation markers. That approach can improve batch consistency without creating the regulatory burden of a new formulation.

What formulation patents could protect Focinvez or competing fosaprepitant products?

The core Focinvez commercial position is likely driven by regulatory approval and generic competition rather than a broad, publicly visible formulation-patent estate. The commercially relevant patent categories for fosaprepitant products are:

Composition and formulation patents

These may cover:

• Particular surfactant concentrations.
• Specific pH ranges.
• Chelating-agent combinations.
• Freeze-dried cakes.
• Reconstitution systems.
• Solvent or cosolvent systems.
• Stabilized fosaprepitant salts.
• Reduced-degradation formulations.
• Specific impurity limits or degradation profiles.

A formulation patent is most valuable when it protects a necessary technical solution rather than a readily replaceable excipient choice. A claim limited to a conventional polysorbate 80 concentration may be easier to design around than a claim covering a defined stability profile produced by a narrow combination of pH, chelator, surfactant, and lyophilization conditions.

Method-of-use patents

Method-of-use claims may address:

• Prevention of acute chemotherapy-induced nausea and vomiting.
• Prevention of delayed nausea and vomiting.
• Use with highly emetogenic chemotherapy.
• Use in pediatric patients.
• Use with specific chemotherapy classes.
• Dosing schedules or infusion sequences.

The clinical use of fosaprepitant overlaps with the established use of aprepitant. The strength of a method-of-use claim depends on claim specificity, remaining term, enforceability, and whether the relevant indication appears in the generic product label.

Manufacturing patents

Manufacturing protection may cover:

• Preparation of fosaprepitant dimeglumine.
• Crystallization and particle-size control.
• Salt formation.
• Purification and impurity removal.
• Sterile filtration or aseptic processing.
• Lyophilization cycles.
• Reconstitution and filling processes.

Manufacturing claims can create practical barriers even when they do not block a competing finished product. A competitor may avoid infringement through an alternative synthetic route, but process changes can increase cost, impurity risk, and regulatory comparability requirements.

Device and packaging rights

Commercial opportunities may involve:

• Dual-chamber reconstitution systems.
• Closed-system transfer devices.
• Pharmacy-ready kits.
• Adapter-compatible vial systems.
• Ready-to-use infusion bags.
• Packaging that limits surfactant interaction or moisture ingress.

These rights may produce a commercial advantage without changing the approved active ingredient.

When does Focinvez lose exclusivity?

Focinvez does not have a single universal exclusivity date that applies across all markets. Exclusivity depends on the jurisdiction, the marketing authorization route, applicable data-protection rules, and any valid patents covering the product or its use.

In the European Union, Focinvez is an authorized medicinal product with a generic relationship to the reference product Emend IV. EU generic products generally rely on the reference product's regulatory dossier after the applicable data and market-protection periods have elapsed. The product's commercial protection is therefore primarily linked to:

• Regulatory authorization.
• Any remaining formulation or process patents.
• National procurement contracts.
• Hospital formulary adoption.
• Manufacturing capacity.
• Pricing and supply reliability.

Unlike the United States, the EU does not use the Orange Book as the central public patent-listing mechanism. Patent rights must be assessed through European Patent Office records, national registers, the Unified Patent Court system where applicable, and local litigation records.

A product-level expiry date should not be inferred solely from the Focinvez authorization date. The relevant analysis is patent-by-patent and country-by-country.

What is the Orange Book status of Focinvez?

Focinvez has no U.S. Orange Book listing because Focinvez is an EU product rather than an FDA-approved U.S. brand. The Orange Book status of U.S. fosaprepitant products must be reviewed separately.

The U.S. market includes Emend IV and generic fosaprepitant products approved through the abbreviated new drug application pathway. Those products may have different labeling, inactive ingredients, patent certifications, and launch restrictions. A U.S. generic applicant's Paragraph IV position against a listed patent does not automatically affect Focinvez in Europe.

For commercial planning, the relevant distinction is:

Issue	Focinvez in the EU	U.S. fosaprepitant products
Orange Book listing	No	Applies to FDA-listed reference products
Generic pathway	EU generic application	ANDA pathway
Patent challenge	National, European, or UPC proceedings	Paragraph IV certification and Hatch-Waxman litigation
Regulatory exclusivity	EU data and market protection	FDA exclusivity rules
Main buyers	Hospitals and national systems	Hospitals, group purchasing organizations, distributors
Labeling	EU product information	U.S. prescribing information

Which companies are challenging or competing with Focinvez?

The competitive landscape includes four groups.

Emend and branded fosaprepitant

Emend established the intravenous fosaprepitant market. The brand retains value where physicians and hospitals prioritize historical familiarity, supply assurance, or protocol continuity. Its pricing position is vulnerable to generic procurement.

Generic fosaprepitant manufacturers

Generic competitors can compete through lower acquisition cost, reliable supply, and broad hospital distribution. Their technical differentiation usually comes from manufacturing efficiency, vial configuration, stability, and packaging rather than a new clinical profile.

Oral aprepitant suppliers

Oral aprepitant is a direct commercial alternative for patients who can swallow and absorb oral medication. It can reduce preparation burden and, in some settings, lower treatment cost. Intravenous fosaprepitant retains an advantage when oral administration is impractical or when chemotherapy protocols favor intravenous antiemetic delivery.

Alternative antiemetic regimens

Netupitant-palonosetron combinations, rolapitant, ondansetron, palonosetron, dexamethasone, and olanzapine compete for the same antiemetic budget. The relevant comparison is not limited to the NK1 antagonist class. Hospitals assess the total regimen cost, administration time, protocol compliance, and reduction in breakthrough nausea and vomiting.

What commercial opportunities exist for Focinvez excipient innovation?

Ready-to-use intravenous presentation

A ready-to-use solution or infusion bag could reduce pharmacy labor, reconstitution errors, and administration delays. The main technical barriers are solution stability, container compatibility, sterilization strategy, and post-manufacture shelf-life.

The commercial value is highest in high-volume oncology centers where pharmacy preparation costs are material. A ready-to-use format could command a premium if it reduces compounding time and waste while maintaining competitive total treatment cost.

Faster reconstitution

A formulation with shorter reconstitution time could differentiate Focinvez without changing the active ingredient. Relevant performance metrics include:

• Time to complete dissolution.
• Foam formation.
• Need for manual swirling.
• Visible particles.
• Reconstitution volume.
• Stability after dilution.
• Compatibility with standard infusion bags.

This opportunity is particularly relevant to outpatient oncology clinics and centralized hospital pharmacies.

Surfactant-risk reduction

A lower-polysorbate formulation could address procurement concerns and improve long-term raw-material resilience. The commercial claim must be supported by measurable benefits such as improved oxidative stability, fewer compatibility limitations, or reduced visible particulate risk.

Pediatric and low-volume formats

Pediatric oncology creates demand for accurate low-volume dosing and reduced preparation waste. Opportunities include smaller vial sizes, improved dose withdrawal, and packaging designed for pharmacy-controlled fractional dosing. Any pediatric presentation would require careful assessment of dose proportionality, preservative status, microbial risk, and labeling.

Supply-chain resilience

Excipient strategy can create value through dual sourcing and regional manufacturing. The highest-priority materials are polysorbate 80 and specialized sterile-packaging components. A manufacturer with qualified secondary suppliers, validated alternate grades, and safety-stock policies can win hospital contracts even without the lowest unit price.

Improved compatibility information

Clearer validated data on compatible diluents, infusion bags, administration sets, and post-reconstitution storage can reduce pharmacy uncertainty. Product information that supports standard oncology workflows may improve formulary adoption.

How strong is the Focinvez patent estate?

The commercial patent strength appears moderate rather than dominant when assessed at the product-platform level.

Patent category	Likely strategic value	Main weakness
Active-ingredient composition	Low to moderate for a mature product	Fosaprepitant is established and may have expired core protection
Lyophilized formulation	Moderate	Competitors may use alternative excipient ratios or processes
Polysorbate-based stability	Moderate	Narrow claims may be designed around
Method of use	Moderate	Label and indication overlap can limit enforcement value
Manufacturing process	Moderate to high if process is difficult to replicate	Alternative routes may remain available
Packaging and delivery	Low to moderate	Protection may be commercially useful but narrow
Regulatory position	High in selected hospital markets	Vulnerable to generic price competition

The strongest defensible position would combine formulation claims with process controls and a differentiated presentation. A single conventional excipient combination is less likely to create durable market exclusivity than a portfolio covering composition, stability performance, manufacturing, and pharmacy-use features.

What generic launch risks exist for Focinvez?

Generic entry risk is high because fosaprepitant is an established small-molecule injectable with a defined clinical use. The principal risks are:

• Price erosion after multiple suppliers enter.
• Hospital tender substitution.
• Parallel procurement pressure across EU markets.
• Loss of branded preference once protocols permit substitution.
• Supply interruptions that shift volume to competitors.
• Formulation similarity that limits meaningful differentiation.
• Manufacturing deviations involving sterility, particulate matter, or reconstitution performance.

The main barriers are technical rather than clinical. Injectable generics must demonstrate control of sterility, impurities, particulate matter, container closure, reconstitution, dilution stability, and administration compatibility. Those requirements raise development costs but do not create the same barriers as a complex biologic or a highly device-dependent product.

How does Focinvez compare with Emend IV and oral aprepitant?

Factor	Focinvez	Emend IV	Oral aprepitant
Active moiety	Fosaprepitant prodrug	Fosaprepitant prodrug	Aprepitant
Administration	IV infusion	IV infusion	Oral
Preparation burden	Requires reconstitution and dilution	Requires reconstitution and dilution, depending on presentation	Minimal pharmacy preparation
Use when oral intake is difficult	Strong	Strong	Limited
Excipient focus	Polysorbate 80, edetate, lactose, pH agents	Similar reference-product considerations	Solid-dose excipients
Main differentiation	Price, supply, workflow, formulation	Brand familiarity and historical use	Convenience and cost
Primary patent risk	Formulation, process, use	Reference-product and listed-patent history	Oral formulation and use patents
Main buyer concern	Total cost and reliable supply	Brand premium justification	Patient suitability and regimen fit

Focinvez has the clearest commercial advantage when hospitals seek a lower-cost intravenous substitute without changing established chemotherapy protocols. Oral aprepitant is a stronger alternative where oral administration is practical and pharmacy labor is a major cost driver.

What FDA regulatory issues affect a Focinvez commercialization strategy?

Focinvez cannot be commercialized in the United States under its EU authorization. A U.S. launch would require an FDA application, most likely an ANDA if the product qualifies as therapeutically equivalent to an approved reference product, or another pathway if formulation or product differences prevent a standard abbreviated approach.

U.S. development would require assessment of:

• Active ingredient and salt form.
• Inactive-ingredient acceptability for intravenous use.
• Sterile manufacturing controls.
• Comparative pharmaceutical equivalence.
• Container-closure systems.
• Reconstitution and dilution performance.
• Labeling differences.
• Patent certifications.
• Potential Paragraph IV litigation.
• FDA inactive-ingredient database precedents.

The FDA Inactive Ingredient Database can help assess whether proposed excipient levels and routes of administration have precedent, but database presence does not replace product-specific quality and safety requirements.[3]

What licensing deals could create value around Focinvez?

The most commercially credible licensing opportunities are formulation and supply-chain transactions rather than discovery collaborations.

Potential deal structures include:

• Regional distribution rights for hospital markets.
• Co-development of a ready-to-use infusion presentation.
• Licensing of a surfactant-reduced formulation.
• Contract manufacturing with dual-source excipient qualification.
• In-licensing of a fast-reconstitution lyophilization process.
• Hospital tender partnerships with guaranteed supply volumes.
• Technology transfer for sterile filling and lyophilization.
• Packaging licenses for closed-system oncology administration.

A licensing partner should value measurable operational benefits: lower pharmacy labor, fewer discarded vials, longer in-use stability, reduced preparation errors, and improved supply continuity. Claims based only on a familiar excipient substitution are unlikely to justify a substantial royalty unless supported by enforceable intellectual property and validated manufacturing advantages.

Key Takeaways

• Focinvez is an EU-authorized intravenous fosaprepitant product supplied as a 150 mg lyophilized powder.
• Its core excipient system includes polysorbate 80, disodium edetate, lactose, sodium hydroxide, and hydrochloric acid.
• Polysorbate 80 is the principal excipient risk and the most plausible target for stability, sourcing, and formulation innovation.
• The strongest commercial opportunities are ready-to-use delivery, faster reconstitution, pediatric formats, supply resilience, and improved compatibility data.
• Focinvez has no U.S. Orange Book status because it is not itself an FDA-approved U.S. product.
• Generic entry risk is high because fosaprepitant is an established small-molecule injectable.
• Durable differentiation is more likely from a combined formulation, manufacturing, packaging, and workflow portfolio than from a single conventional excipient claim.
• The most attractive licensing opportunities involve hospital-use efficiency and sterile supply-chain control.

FAQs

Is Focinvez the same drug as Emend IV?

Focinvez and Emend IV both contain fosaprepitant as the intravenous prodrug of aprepitant, but they are separate medicinal products with separate regulatory authorizations and labeling.

Does Focinvez contain polysorbate 80?

Yes. Polysorbate 80 is identified in the Focinvez product information and functions primarily as a solubilizing and stabilizing excipient.[1]

Can Focinvez be converted into a ready-to-use infusion bag?

A ready-to-use presentation would require a new formulation and product-development program addressing solution stability, sterility, container compatibility, particulate control, and in-use storage. It cannot be assumed to be interchangeable with the approved lyophilized vial.

Is Focinvez suitable for pediatric oncology use?

The EU product information includes pediatric use provisions for fosaprepitant in specified age groups and clinical settings. Pediatric dosing and administration must follow the authorized product information and applicable chemotherapy protocol.[1]

What is the most valuable excipient patent opportunity for fosaprepitant?

A patent covering a validated stable intravenous formulation with reduced surfactant dependence, improved reconstitution, defined impurity control, and commercially useful shelf-life would generally have greater strategic value than a narrow claim to a conventional excipient ratio.

References

1. European Medicines Agency. (n.d.). Focinvez: EPAR - Product information. European Union.

2. European Medicines Agency. (n.d.). Emend: EPAR - Product information. European Union.

3. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. FDA.

4. U.S. Food and Drug Administration. (2022). Emend for injection prescribing information. FDA.

5. International Council for Harmonisation. (2009). ICH Q8(R2): Pharmaceutical development. ICH.

6. International Council for Harmonisation. (2005). ICH Q9: Quality risk management. ICH.